drugset / Trial / NCT06281678
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Timeline
- Start
- 2024-04-08
- Primary completion
- 2026-03-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI363 | Protein / enzyme biologic | — | Intravenous |